FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200540557> ?p ?o ?g. }

• W4200540557 abstract "Given the expanding clinical use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis), there is a significant need for optimal strategies with which to treat patients whose cancer progresses while using a PARPi. However, the treatment consensus after PARPi has not been established. The aim of the Korean Gynecologic Oncology Group (KGOG) 3056/NIRVANA-R trial is to investigate the efficacy of niraparib in combination with bevacizumab as a maintenance therapy in platinum-sensitive ovarian cancer patients who were previously treated with a PARPi.The KGOG 3056/NIRVANA-R is a multi-centre, investigator-initiated, single-arm, phase II trial of patients with platinum-sensitive recurrent ovarian cancer recruited from seven KGOG sites. This study included patients with platinum-sensitive recurrent epithelial ovarian cancer who received at least 2 previous courses of platinum-containing therapy and had been treated with a PARPi. Mucinous histology type was excluded. Patients who had responded to the last platinum regimen (either complete or partial response) were eligible to participate in this study. Forty-four patients will be recruited. All enrolled patients are treated with niraparib and bevacizumab for maintenance therapy until disease progression, unacceptable toxicity, or withdrawal of patient consent. The primary endpoint of the study is 6-month progression-free survival rate. Accrual is expected to be completed in 2022, followed by presentation of results in 2023.ClinicalTrials.gov Identifier: NCT04734665." @default.
• W4200540557 created "2021-12-31" @default.
• W4200540557 creator A5011850028 @default.
• W4200540557 creator A5024381278 @default.
• W4200540557 creator A5035365662 @default.
• W4200540557 creator A5037036233 @default.
• W4200540557 creator A5057234589 @default.
• W4200540557 creator A5064859438 @default.
• W4200540557 creator A5072456286 @default.
• W4200540557 creator A5074645251 @default.
• W4200540557 date "2022-01-01" @default.
• W4200540557 modified "2023-10-16" @default.
• W4200540557 title "A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial" @default.
• W4200540557 cites W2071966564 @default.
• W4200540557 cites W2113122060 @default.
• W4200540557 cites W2118010724 @default.
• W4200540557 cites W2127560962 @default.
• W4200540557 cites W2135947389 @default.
• W4200540557 cites W2151509048 @default.
• W4200540557 cites W2157899948 @default.
• W4200540557 cites W2179105349 @default.
• W4200540557 cites W2325848599 @default.
• W4200540557 cites W2344322811 @default.
• W4200540557 cites W2528228811 @default.
• W4200540557 cites W2623263876 @default.
• W4200540557 cites W2737389832 @default.
• W4200540557 cites W2754327139 @default.
• W4200540557 cites W2763141358 @default.
• W4200540557 cites W2887959853 @default.
• W4200540557 cites W2897430921 @default.
• W4200540557 cites W2946425279 @default.
• W4200540557 cites W2947257322 @default.
• W4200540557 cites W2947993621 @default.
• W4200540557 cites W2954686273 @default.
• W4200540557 cites W2955997569 @default.
• W4200540557 cites W2968820602 @default.
• W4200540557 cites W2970135300 @default.
• W4200540557 cites W2975141952 @default.
• W4200540557 cites W2976139792 @default.
• W4200540557 cites W2994977341 @default.
• W4200540557 cites W3026903046 @default.
• W4200540557 cites W3126466062 @default.
• W4200540557 cites W3128646645 @default.
• W4200540557 cites W3204360130 @default.
• W4200540557 doi "https://doi.org/10.3802/jgo.2022.33.e12" @default.
• W4200540557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34910393" @default.
• W4200540557 hasPublicationYear "2022" @default.
• W4200540557 type Work @default.
• W4200540557 citedByCount "4" @default.
• W4200540557 countsByYear W42005405572022 @default.
• W4200540557 countsByYear W42005405572023 @default.
• W4200540557 crossrefType "journal-article" @default.
• W4200540557 hasAuthorship W4200540557A5011850028 @default.
• W4200540557 hasAuthorship W4200540557A5024381278 @default.
• W4200540557 hasAuthorship W4200540557A5035365662 @default.
• W4200540557 hasAuthorship W4200540557A5037036233 @default.
• W4200540557 hasAuthorship W4200540557A5057234589 @default.
• W4200540557 hasAuthorship W4200540557A5064859438 @default.
• W4200540557 hasAuthorship W4200540557A5072456286 @default.
• W4200540557 hasAuthorship W4200540557A5074645251 @default.
• W4200540557 hasBestOaLocation W42005405571 @default.
• W4200540557 hasConcept C104317684 @default.
• W4200540557 hasConcept C121608353 @default.
• W4200540557 hasConcept C126322002 @default.
• W4200540557 hasConcept C143998085 @default.
• W4200540557 hasConcept C182979987 @default.
• W4200540557 hasConcept C185592680 @default.
• W4200540557 hasConcept C203092338 @default.
• W4200540557 hasConcept C2776694085 @default.
• W4200540557 hasConcept C2777802072 @default.
• W4200540557 hasConcept C2778283404 @default.
• W4200540557 hasConcept C2779138821 @default.
• W4200540557 hasConcept C2779962180 @default.
• W4200540557 hasConcept C2780427987 @default.
• W4200540557 hasConcept C2780435969 @default.
• W4200540557 hasConcept C2780739268 @default.
• W4200540557 hasConcept C2781413609 @default.
• W4200540557 hasConcept C535046627 @default.
• W4200540557 hasConcept C55493867 @default.
• W4200540557 hasConcept C71924100 @default.
• W4200540557 hasConcept C82381507 @default.
• W4200540557 hasConceptScore W4200540557C104317684 @default.
• W4200540557 hasConceptScore W4200540557C121608353 @default.
• W4200540557 hasConceptScore W4200540557C126322002 @default.
• W4200540557 hasConceptScore W4200540557C143998085 @default.
• W4200540557 hasConceptScore W4200540557C182979987 @default.
• W4200540557 hasConceptScore W4200540557C185592680 @default.
• W4200540557 hasConceptScore W4200540557C203092338 @default.
• W4200540557 hasConceptScore W4200540557C2776694085 @default.
• W4200540557 hasConceptScore W4200540557C2777802072 @default.
• W4200540557 hasConceptScore W4200540557C2778283404 @default.
• W4200540557 hasConceptScore W4200540557C2779138821 @default.
• W4200540557 hasConceptScore W4200540557C2779962180 @default.
• W4200540557 hasConceptScore W4200540557C2780427987 @default.
• W4200540557 hasConceptScore W4200540557C2780435969 @default.
• W4200540557 hasConceptScore W4200540557C2780739268 @default.
• W4200540557 hasConceptScore W4200540557C2781413609 @default.
• W4200540557 hasConceptScore W4200540557C535046627 @default.
• W4200540557 hasConceptScore W4200540557C55493867 @default.
• W4200540557 hasConceptScore W4200540557C71924100 @default.

• next